ARTICLE | Clinical News
Anti-oxLDL: Completed Phase IIa enrollment
March 12, 2012 7:00 AM UTC
BioInvent completed enrollment of 147 patients with evidence of vascular inflammation in the double-blind, placebo-controlled, North American Phase IIa GLACIER trial evaluating single or repeating dos...